Gattex (teduglutide) is administered as a subcutaneous injection once daily. It comes as a lyophilized (freeze-dried) powder in a single-use vial that must be reconstituted with sterile water for injection (diluent) provided in a prefilled syringe. Proper preparation and administration technique are critical for patient safety and medication efficacy.

• Reconstitution: The powder must be completely dissolved in the diluent. Gently roll the vial between the palms of your hands for about 15 seconds; do not shake. Allow it to sit for about 2 minutes to ensure complete dissolution. The reconstituted solution should be clear and colorless to pale yellow, without particles. Use the reconstituted solution within 3 hours.
• Injection Sites: The injection should be administered subcutaneously into the abdomen (avoiding the area 2 inches around the navel), thigh, or upper arm. It is important to rotate injection sites daily to minimize localized skin reactions. Do not inject into skin that is tender, bruised, red, or hard.
• Administration Time: Gattex should be injected once daily at approximately the same time each day.
• Training: Patients and/or caregivers will receive comprehensive training from a healthcare professional on the proper technique for reconstituting and administering the injection.

It is imperative not to inject Gattex intravenously or intramuscularly.

Gattex’s active ingredient, teduglutide, is an analog of glucagon-like peptide-2 (GLP-2), a naturally occurring hormone produced in the intestinal lining. GLP-2 plays a crucial role in regulating intestinal growth, function, and repair. In patients with Short Bowel Syndrome, the body’s natural production or effectiveness of GLP-2 may be insufficient to support adequate intestinal adaptation.

Teduglutide works by:

• Stimulating Intestinal Growth: It binds to GLP-2 receptors located in the intestine, stimulating the growth of the small bowel lining. This includes increasing the height of the intestinal villi (finger-like projections) and the depth of the crypts (invaginations between villi).
• Enhancing Absorption: By increasing the surface area and improving the integrity of the intestinal lining, Gattex enhances the small bowel’s ability to absorb nutrients, fluids, and electrolytes from food and oral intake.
• Reducing Secretions: It also has effects that may reduce gastrointestinal secretions, further contributing to improved fluid balance.

Through these mechanisms, Gattex helps to improve intestinal adaptation and function in patients with SBS, thereby reducing their dependency on intravenous nutrition and hydration.

While Gattex (teduglutide) offers significant benefits for SBS, it is associated with a range of side effects that patients and healthcare providers should be aware of. Many of these side effects are gastrointestinal, reflecting the drug’s action on the gut.

Common side effects (often greater than 10%) include:

• Gastrointestinal: Abdominal pain, abdominal distension (swelling), nausea, vomiting, flatulence (gas), and complications related to a gastrointestinal stoma (if present).
• Infection: Upper respiratory tract infection, nasopharyngitis (common cold), headache.
• Injection Site Reactions: Redness, pain, swelling, bruising, or itching at the injection site.
• Fluid-related: Fluid overload (which may manifest as swelling, especially in the hands or feet, or shortness of breath).

Less common but serious side effects can include:

• Biliary and Pancreatic Disease: Cholecystitis, cholangitis, cholelithiasis (gallstones), and pancreatitis.
• Intestinal Obstruction: Blockage of the bowel.
• Increased Risk of Neoplasia/Polyps: Potential for acceleration of pre-existing abnormal cell growth, including intestinal polyps or certain cancers.

Any new or worsening symptoms, especially severe abdominal pain, fever, chills, or unusual swelling, should be reported to a doctor immediately.

Gattex (teduglutide) carries several important warnings and precautions, primarily due to its effect on cell growth and potential systemic implications, necessitating careful monitoring.

• Risk of Neoplastic Growth Acceleration: Gattex has the potential to cause hyperplastic (overgrowth) changes and accelerate the growth of pre-existing abnormal cells, including intestinal polyps and certain malignancies (gastrointestinal, liver, gallbladder, pancreas).
  • Screening: Adult patients require a colonoscopy with polyp removal within 6 months prior to starting Gattex, and a follow-up colonoscopy at the end of 1 year of treatment. Subsequent colonoscopies are recommended at least every 5 years, or as needed if polyps are found. Pediatric patients require stool occult blood testing before starting and annually during treatment; if positive, further evaluation for polyps is needed.
  • Active Malignancy: Gattex is contraindicated in patients with active gastrointestinal malignancy. For other active non-gastrointestinal malignancies, the decision to continue Gattex should be based on a risk-benefit assessment.
• Intestinal Obstruction: Intestinal obstruction has been reported. If a patient develops signs or symptoms of obstruction (e.g., severe constipation, abdominal pain/swelling, nausea, vomiting), Gattex should be temporarily discontinued, and the patient evaluated.
• Biliary and Pancreatic Disease: Patients should undergo laboratory assessments (bilirubin, alkaline phosphatase, lipase, amylase) before starting Gattex and every 6 months during treatment to monitor for biliary or pancreatic issues (e.g., cholecystitis, cholangitis, pancreatitis).
• Fluid Imbalance and Fluid Overload: Close monitoring for fluid overload is essential, particularly in patients with cardiovascular disease, as Gattex can increase fluid absorption. Parenteral support may need adjustment.
• Increased Absorption of Oral Medications: As mentioned, Gattex may increase the absorption of concomitant oral medications. Careful monitoring and dose adjustments of other drugs are necessary.

Gattex (teduglutide) has a notable potential to interact with other medications, primarily due to its mechanism of action which enhances the absorption capabilities of the small intestine.

• Increased Absorption of Oral Medications: Teduglutide can increase the absorption of concurrently administered oral medications. This is particularly important for drugs that have a narrow therapeutic index (where small changes in dosage can have significant effects) or those that require careful titration. Examples include benzodiazepines (e.g., prazepam, though not commonly used), opioids, digoxin, and antihypertensive drugs. Patients taking such medications may require dose adjustments or more frequent monitoring by their healthcare provider.
• No Known Cytochrome P450 or P-glycoprotein Interactions: In vitro studies suggest that teduglutide does not directly affect cytochrome P450 enzymes (a major system for drug metabolism) or P-glycoprotein (an efflux transporter), which limits pharmacokinetic interactions through these pathways.

It is absolutely crucial for patients to inform their doctor and pharmacist about all oral medications, including prescription drugs, over-the-counter products, vitamins, and herbal supplements, before starting Gattex. Close monitoring and potential dose adjustments of other medications may be necessary to ensure patient safety and optimal treatment outcomes.

The dosage of Gattex (teduglutide) is weight-based and is crucial for achieving optimal results while minimizing potential side effects. It is administered as a subcutaneous injection once daily.

• Recommended Dose (Adults and Pediatric Patients 1 year and older): The standard recommended daily dose is 0.05 mg/kg of body weight, administered once daily by subcutaneous injection.
• Renal Impairment: For adult and pediatric patients with moderate to severe renal impairment (estimated glomerular filtration rate less than 60 mL/min/1.73 m²), including those with end-stage renal disease, the recommended dosage is reduced to 0.025 mg/kg once daily.
• Administration Schedule: Gattex should be administered at approximately the same time each day.
• Missed Dose: If a dose is missed, it should be taken as soon as possible on that same day. Do not take two doses on the same day to make up for a missed dose.
• Preparation: As a powder for injection, it must be reconstituted with the provided diluent. Patients and caregivers receive detailed training on this process.

The specific dose is calculated by the healthcare provider, and patients should strictly follow the prescribed dosage and administration instructions.

Gattex (teduglutide) is a prescription-only medication and is subject to specific requirements due to its specialized use and associated risks. It cannot be obtained over-the-counter.

Key aspects of its prescription status and associated programs:

• Specialty Medication: Gattex is considered a specialty medication and is typically prescribed by or in consultation with a gastroenterologist or a physician with expertise in managing Short Bowel Syndrome.
• Risk Evaluation and Mitigation Strategy (REMS): Gattex is part of a REMS program (GATTEX REMS) in some regions. This program ensures that patients, caregivers, and healthcare providers are informed about the significant risks associated with the medication, particularly concerning the potential for acceleration of neoplastic growth (including colon polyps), intestinal obstruction, and biliary/pancreatic disease.
• Patient Enrollment: Patients typically need to be enrolled in the GATTEX REMS program and receive specific educational materials, including a Medication Guide, before starting therapy.
• Prior Authorization: Due to its high cost and specialized indication, Gattex often requires prior authorization from insurance companies.
• Close Monitoring: Ongoing close monitoring by a healthcare provider, including regular colonoscopies (for adults) or stool occult blood tests (for pediatric patients), and laboratory assessments, is a mandatory part of therapy.

Patients considering Gattex treatment will undergo a comprehensive evaluation and be provided with extensive information by their healthcare team.

1. What is Gattex?

• Gattex is the brand name for teduglutide, a GLP-2 analogue used to enhance intestinal absorption.

2. How does Gattex work?

• It mimics glucagon-like peptide-2 (GLP-2), promoting intestinal growth, increasing villus height and blood flow, and improving nutrient/fluid absorption.

3. What is Gattex used to treat?

• Short bowel syndrome (SBS) in patients dependent on parenteral support (intravenous fluids/nutrition).

4. Who is an appropriate candidate for Gattex?

• Patients with SBS requiring parenteral support who have an intact or partially intact gastrointestinal tract and meet prescribing criteria.

5. How is Gattex administered?

• Subcutaneous injection, typically once daily (dose and schedule per prescribing information).

6. How long does it take to see benefits from Gattex?

• Some patients show reduced parenteral requirements within weeks to months; full response may take several months.

7. What are common side effects of Gattex?

• Abdominal pain, injection-site reactions, nausea, headache, and potential fluid overload.

8. Are there serious risks associated with Gattex?

• Possible increased risk of intestinal neoplasia or polyps, biliary disease, and fluid/electrolyte imbalance; requires monitoring.

9. Does Gattex increase the risk of cancer?

• Animal and some human data raise concerns about intestinal epithelial proliferation; colonoscopic surveillance and polyp management are recommended per guidelines.

10. Can Gattex be used in children?

• Pediatric use depends on regulatory approvals and specialist guidance; dosing and safety must be determined by pediatric specialists.

11. How is therapy with Gattex monitored?

• Monitor fluid status, electrolytes, weight, abdominal symptoms, liver function, and scheduled colonoscopic surveillance for polyps as recommended.

12. Can Gattex reduce or eliminate parenteral nutrition?

• Many patients reduce parenteral volume/frequency; some may achieve full enteral autonomy, but not all patients will.

13. Are there contraindications to Gattex?

• Known hypersensitivity to teduglutide or its components; caution or contraindication may apply in patients with active gastrointestinal malignancy.

14. How should Gattex be stored?

• Store refrigerated (follow manufacturer’s storage instructions); protect from light and do not freeze.

15. Can Gattex be used with other SBS treatments?

• It can be used alongside dietary management, antimotility agents, antisecretory agents, and supportive care as guided by specialists.

16. What should I do if I miss a dose?

• Follow the manufacturer’s and prescriber’s guidance—typically administer as soon as remembered unless near the time for the next dose; do not double-dose.

17. Is Gattex covered by insurance?

• Coverage varies; prior authorization is often required due to high cost and specialty indication.

18. Are there drug interactions with Gattex?

• No major systemic drug interactions are well established due to its peptide nature, but monitor concurrent therapies affecting fluid/electrolyte balance.

19. Can Gattex be stopped once started?

• Yes, but stopping may lead to return of parenteral needs; decisions should be made with the treating specialist and involve monitoring.

20. Where should Gattex be prescribed and managed?

• By specialists experienced in intestinal failure/SBS (gastroenterologists, transplant/intestine rehabilitation teams) with multidisciplinary support.